The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
Related to this article
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR TKI–pretreated advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
3
Enzalutamide Plus Talazoparib Shows Activity in mHSPC
4
FDA Approves First CELMoD Agent, With Dana-Farber Helping Advance Its Development
5